Sunday, 27 September, 2020, 1:36 PM
latest SC lawyer Yunus Ali Akhand suspended        MC College gang rape: Prime accused among 2 held      
Home International

India halts Serum's AstraZeneca vaccine trials

Published : Saturday, 12 September, 2020 at 2:14 PM  Count : 282

A man walks past a signpost of India's Serum Institute, the world's largest maker of vaccines, which is developing a vaccine against the COVID-19 at its laboratory in Pune, India, May 18, 2020. Photo: Reuters

A man walks past a signpost of India's Serum Institute, the world's largest maker of vaccines, which is developing a vaccine against the COVID-19 at its laboratory in Pune, India, May 18, 2020. Photo: Reuters

India's drug regulator has asked Serum Institute of India to suspend recruitment in its clinical trials of AstraZeneca Plc's potential COVID-19 vaccine in the country until further orders, Reuters partner ANI reported on Friday.

VG Somani, the drugs controller general of India, has also asked for increased safety monitoring of those already vaccinated with the experimental vaccine, ANI reported, citing an order issued by the regulator.

The move places further restrictions on the trials, which have already been put on hold by Serum on Thursday after the DCGI had asked the vaccine maker for details on the suspension of trials overseas, in a show-cause notice that was reviewed by Reuters.

Friday's order has been issued after Serum responded to the show-cause notice, according to ANI.

Somani had warned that Serum could face action if it did not offer an explanation for why the trials should not be suspended until patient safety is established, after AstraZeneca decided earlier in the week to pause global trials in the wake of an unexplained illness in a study participant.

The DCGI, Serum and AstraZeneca did not immediately respond to Reuters' requests for comment.

The drugs regulator had given last month Serum approval to run mid- to late-stage clinical trials on the leading COVID-19 vaccine candidate to determine its safety and ability to trigger immune response.





Reuters/MUS

Related Topics

India   AstraZeneca  




« PreviousNext »



Latest News
Most Read News
Editor : Iqbal Sobhan Chowdhury
Published by the Editor on behalf of the Observer Ltd. from Globe Printers, 24/A, New Eskaton Road, Ramna, Dhaka.
Editorial, News and Commercial Offices : Aziz Bhaban (2nd floor), 93, Motijheel C/A, Dhaka-1000. Phone: PABX 9586651-58; Online: 9513959; Advertisement: 9513663
E-mail: [email protected], [email protected], [email protected], [email protected],   [ABOUT US]     [CONTACT US]   [AD RATE]   Developed & Maintenance by i2soft